AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 213.98B +31.6% |
| Revenue (ttm) | 45.77B +9.9% |
| Net Income | 7.87B +33.7% |
| EPS | 5.03 +33.6% |
| Shares Out | 1.55B |
| PE Ratio | 27.44 |
| Forward PE | 17.31 |
| Dividend | 2.36 (1.71%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | 365,257 |
| Open | 13,632 |
| Previous Close | 13,796 |
| Day's Range | 13,488 - 13,716 |
| 52-Week Range | 10,103 - 15,732 |
| Beta | 0.21 |
| Analysts | Buy |
| Price Target | 16,597.21 (+21.91%) |
| Earnings Date | Jul 27, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is 16,597p, which is an increase of 21.91% from the latest price.
News
AstraZeneca (AZN) Advances Elecoglipron to Phase 3 Trials After Positive Results
AstraZeneca (AZN) Advances Elecoglipron to Phase 3 Trials After Positive Results
AstraZeneca Transcript: Investor update
Phase IIb data for elecoglipron show strong efficacy in weight loss and glycemic control, supporting advancement to phase III trials targeting obesity, type 2 diabetes, and related comorbidities. The strategy emphasizes combination therapies, global reach, and tailored patient solutions.
AstraZeneca Slides: Investor update
AstraZeneca has posted slides in relation to its latest quarterly earnings report, which was published on June 8, 2026.
AstraZeneca (AZN) Reports Promising Phase IIb Results for Elecoglipron
AstraZeneca (AZN) Reports Promising Phase IIb Results for Elecoglipron
AstraZeneca advancing elecoglipron into Phase 3 program in obesity, T2D
Positive results from the VISTA and SOLSTICE Phase IIb trials of elecoglipron, an oral small molecule GLP-1 receptor agonist, “unlock the next chapter in AstraZeneca’s (AZN) ambition to develop therap...
AstraZeneca obesity pill helps patients lose 10.5% of body weight in trial
AstraZeneca said on Monday that patients lost 10.5% of their body weight after 26 weeks in a mid-stage trial of its experimental obesity pill, as the drugmaker seeks to challenge Novo Nordisk and Eli...
Top 10 London Stock Exchange Stocks to Consider Buying in 2026 for UK Exposure
The London Stock Exchange sees renewed momentum in 2026, with the FTSE 100 surpassing 10,000 points. Key stocks like AstraZeneca and Shell offer growth and resilience amid global economic shifts.
AstraZeneca CEO: AI helps us make smarter choices when developing drugs
AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk quarterly results, drug development, AI integration, and more.
AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer
AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk quarterly results, drug development, AI integration, and more.
AstraZeneca CEO says AI is reshaping drug development — and helping boost the odds of success
AstraZeneca CEO Pascal Soriot said artificial intelligence is helping the company develop medicines faster, identify promising drug targets, and improve the odds of success in costly clinical trials. ...
NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, June 5, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NY...
AstraZeneca PLC (AZN) Shares Surge 3.1% -- What GF Score of 83 Tells Investors
AstraZeneca PLC (AZN) Shares Surge 3.1% -- What GF Score of 83 Tells Investors
AstraZeneca (AZN) Engages with FDA Leadership on Rare Disease Initiatives
AstraZeneca (AZN) Engages with FDA Leadership on Rare Disease Initiatives
FTSE 100 drops amid China banking concerns and falling oil prices
The UK's benchmark FTSE 100 index fell to its lowest level in more than two weeks on Thursday, weighed down by sharp declines in Asia-focused lenders and miners after reports of tighter offshore banki...
AstraZeneca CEO: AI is affecting every part of our company
AstraZeneca CEO Pascal Soriot joins CNBC’s Angelica Peebles to discuss the most promising drugs in AstraZeneca’s pipeline. He says the future is about innovating into new indications with the drugs an...
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment For Ampligen In Pancreatic Cancer; Stock Down
(RTTNews) - AIM ImmunoTech Inc. (AIM), an immune pharma company, announced the final enrolment of subjects in the Phase 2 clinical trial dubbed DURIPANC, evaluating AIM's drug Ampligen (rintatolimod) ...
AstraZeneca (AZN) Benefits from New FDA Guidance on Gene Therapy Development
AstraZeneca (AZN) Benefits from New FDA Guidance on Gene Therapy Development
AstraZeneca's Camizestrant Shows Strong Results in Phase III Trial (AZN)
AstraZeneca's Camizestrant Shows Strong Results in Phase III Trial (AZN)
AstraZeneca (AZN) Reports Promising Phase III Trial Results for Camizestrant
AstraZeneca (AZN) Reports Promising Phase III Trial Results for Camizestrant
AstraZeneca announces additional results from Phase III Serena-6 trial
Further positive results from the Phase III Serena-6 trial showed AstraZeneca’s (AZN) camizestrant plus a cyclin-dependent kinase, CDK, 4/6 inhibitor – palbociclib, ribociclib or abemaciclib – maintai...
AstraZeneca reports ‘further positive results’ from Phase 3 SERENA-6 trial
Further positive results from the Phase III SERENA-6 trial showed AstraZeneca’s (AZN) camizestrant plus a cyclin-dependent kinase 4/6 inhibitor – palbociclib, ribociclib or abemaciclib – maintained it...
Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
WILMINGTON, Del.--(BUSINESS WIRE)--Further positive results from the Phase III SERENA-6 trial showed AstraZeneca's camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor – palbociclib, riboci...
AstraZeneca PLC (AZN) Stock Down 3.2% but Still Overvalued -- GF Score: 84/100
AstraZeneca PLC (AZN) Stock Down 3.2% but Still Overvalued -- GF Score: 84/100
5 Foreign Stocks That Could Beat The S&P 500
James Demmert explains why foreign markets are beating the U.S.—and the five international stocks he thinks can outperform the S&P 500.
AstraZeneca (AZN) Reports Positive Results in Phase III Trial for HCC Treatment
AstraZeneca (AZN) Reports Positive Results in Phase III Trial for HCC Treatment